Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer

, Sandrine M. Caputo, Melanie Leone, Francesca Damiola, Asa Ehlen, Aura Carreira, Pascaline Gaidrat, Alexandra Martins, Rita Dias Brandão, Ana Peixoto, Ana Vega, Claude Houdayer, Capucine Delnatte, Myriam Bronner, Danièle Muller, Laurent Castera, Marine Guillaud-Bataille, Inge Søkilde, Nancy Uhrhammer, Sophie DemontetyHélène Tubeuf, Gaïa Castelain, Uffe Birk Jensen, Ambre Petitalot, Sophie Krieger, Cedrick Lefol, Virginie Moncoutier, Nadia Boutry-Kryza, Henriette Roed Nielsen, Olga Sinilnikova, Dominique Stoppa-Lyonnet, Amanda B. Spurdle, Manuel R. Teixeira, Florence Coulet, Mads Thomassen, Etienne Rouleau

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Germline pathogenic variants in the BRCA2 gene are associated with a cumulative high risk of breast/ovarian cancer. Several BRCA2 variants result in complete loss of the exon-3 at the transcript level. The pathogenicity of these variants and the functional impact of loss of exon 3 have yet to be established. As a collaboration of the COVAR clinical trial group (France), and the ENIGMA consortium for investigating breast cancer gene variants, this study evaluated 8 BRCA2 variants resulting in complete deletion of exon 3. Clinical information for 39 families was gathered from Portugal, France, Denmark and Sweden. Multifactorial likelihood analyses were conducted using information from 293 patients, for 7 out of the 8 variants (including 6 intronic). For all variants combined the likelihood ratio in favor of causality was 4.39*1025. These results provide convincing evidence for the pathogenicity of all examined variants that lead to a total exon 3 skipping, and suggest that other variants that result in complete loss of exon 3 at the molecular level could be associated with a high risk of cancer comparable to that associated with classical pathogenic variants in BRCA1 or BRCA2 gene. In addition, our functional study shows, for the first time, that deletion of exon 3 impairs the ability of cells to survive upon Mitomycin-C treatment, supporting lack of function for the altered BRCA2 protein in these cells. Finally, this study demonstrates that any variant leading to expression of only BRCA2 delta-exon 3 will be associated with an increased risk of breast and ovarian cancer.
Original languageEnglish
Pages (from-to)17334-17348
Number of pages15
JournalOncoTarget
Volume9
Issue number25
DOIs
Publication statusPublished - 3 Apr 2018

Cite this

, Caputo, S. M., Leone, M., Damiola, F., Ehlen, A., Carreira, A., ... Rouleau, E. (2018). Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer. OncoTarget, 9(25), 17334-17348. https://doi.org/10.18632/oncotarget.24671
Caputo, Sandrine M. ; Leone, Melanie ; Damiola, Francesca ; Ehlen, Asa ; Carreira, Aura ; Gaidrat, Pascaline ; Martins, Alexandra ; Dias Brandão, Rita ; Peixoto, Ana ; Vega, Ana ; Houdayer, Claude ; Delnatte, Capucine ; Bronner, Myriam ; Muller, Danièle ; Castera, Laurent ; Guillaud-Bataille, Marine ; Søkilde, Inge ; Uhrhammer, Nancy ; Demontety, Sophie ; Tubeuf, Hélène ; Castelain, Gaïa ; Jensen, Uffe Birk ; Petitalot, Ambre ; Krieger, Sophie ; Lefol, Cedrick ; Moncoutier, Virginie ; Boutry-Kryza, Nadia ; Roed Nielsen, Henriette ; Sinilnikova, Olga ; Stoppa-Lyonnet, Dominique ; Spurdle, Amanda B. ; Teixeira, Manuel R. ; Coulet, Florence ; Thomassen, Mads ; Rouleau, Etienne. / Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer. In: OncoTarget. 2018 ; Vol. 9, No. 25. pp. 17334-17348.
@article{8b131d59e5b54cbba8c086e0cc1ae747,
title = "Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer",
abstract = "Germline pathogenic variants in the BRCA2 gene are associated with a cumulative high risk of breast/ovarian cancer. Several BRCA2 variants result in complete loss of the exon-3 at the transcript level. The pathogenicity of these variants and the functional impact of loss of exon 3 have yet to be established. As a collaboration of the COVAR clinical trial group (France), and the ENIGMA consortium for investigating breast cancer gene variants, this study evaluated 8 BRCA2 variants resulting in complete deletion of exon 3. Clinical information for 39 families was gathered from Portugal, France, Denmark and Sweden. Multifactorial likelihood analyses were conducted using information from 293 patients, for 7 out of the 8 variants (including 6 intronic). For all variants combined the likelihood ratio in favor of causality was 4.39*1025. These results provide convincing evidence for the pathogenicity of all examined variants that lead to a total exon 3 skipping, and suggest that other variants that result in complete loss of exon 3 at the molecular level could be associated with a high risk of cancer comparable to that associated with classical pathogenic variants in BRCA1 or BRCA2 gene. In addition, our functional study shows, for the first time, that deletion of exon 3 impairs the ability of cells to survive upon Mitomycin-C treatment, supporting lack of function for the altered BRCA2 protein in these cells. Finally, this study demonstrates that any variant leading to expression of only BRCA2 delta-exon 3 will be associated with an increased risk of breast and ovarian cancer.",
author = "Caputo, {Sandrine M.} and Melanie Leone and Francesca Damiola and Asa Ehlen and Aura Carreira and Pascaline Gaidrat and Alexandra Martins and {Dias Brand{\~a}o}, Rita and Ana Peixoto and Ana Vega and Claude Houdayer and Capucine Delnatte and Myriam Bronner and Dani{\`e}le Muller and Laurent Castera and Marine Guillaud-Bataille and Inge S{\o}kilde and Nancy Uhrhammer and Sophie Demontety and H{\'e}l{\`e}ne Tubeuf and Ga{\"i}a Castelain and Jensen, {Uffe Birk} and Ambre Petitalot and Sophie Krieger and Cedrick Lefol and Virginie Moncoutier and Nadia Boutry-Kryza and {Roed Nielsen}, Henriette and Olga Sinilnikova and Dominique Stoppa-Lyonnet and Spurdle, {Amanda B.} and Teixeira, {Manuel R.} and Florence Coulet and Mads Thomassen and Etienne Rouleau",
year = "2018",
month = "4",
day = "3",
doi = "10.18632/oncotarget.24671",
language = "English",
volume = "9",
pages = "17334--17348",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "25",

}

Caputo, SM, Leone, M, Damiola, F, Ehlen, A, Carreira, A, Gaidrat, P, Martins, A, Dias Brandão, R, Peixoto, A, Vega, A, Houdayer, C, Delnatte, C, Bronner, M, Muller, D, Castera, L, Guillaud-Bataille, M, Søkilde, I, Uhrhammer, N, Demontety, S, Tubeuf, H, Castelain, G, Jensen, UB, Petitalot, A, Krieger, S, Lefol, C, Moncoutier, V, Boutry-Kryza, N, Roed Nielsen, H, Sinilnikova, O, Stoppa-Lyonnet, D, Spurdle, AB, Teixeira, MR, Coulet, F & Thomassen, M & Rouleau, E 2018, 'Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer', OncoTarget, vol. 9, no. 25, pp. 17334-17348. https://doi.org/10.18632/oncotarget.24671

Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer. /; Caputo, Sandrine M.; Leone, Melanie; Damiola, Francesca; Ehlen, Asa ; Carreira, Aura ; Gaidrat, Pascaline ; Martins, Alexandra ; Dias Brandão, Rita; Peixoto, Ana ; Vega, Ana; Houdayer, Claude; Delnatte, Capucine; Bronner, Myriam ; Muller, Danièle; Castera, Laurent; Guillaud-Bataille, Marine ; Søkilde, Inge ; Uhrhammer, Nancy; Demontety, Sophie ; Tubeuf, Hélène; Castelain, Gaïa ; Jensen, Uffe Birk; Petitalot, Ambre ; Krieger, Sophie ; Lefol, Cedrick; Moncoutier, Virginie; Boutry-Kryza, Nadia; Roed Nielsen, Henriette ; Sinilnikova, Olga ; Stoppa-Lyonnet, Dominique; Spurdle, Amanda B.; Teixeira, Manuel R.; Coulet, Florence ; Thomassen, Mads; Rouleau, Etienne.

In: OncoTarget, Vol. 9, No. 25, 03.04.2018, p. 17334-17348.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer

AU - Caputo, Sandrine M.

AU - Leone, Melanie

AU - Damiola, Francesca

AU - Ehlen, Asa

AU - Carreira, Aura

AU - Gaidrat, Pascaline

AU - Martins, Alexandra

AU - Dias Brandão, Rita

AU - Peixoto, Ana

AU - Vega, Ana

AU - Houdayer, Claude

AU - Delnatte, Capucine

AU - Bronner, Myriam

AU - Muller, Danièle

AU - Castera, Laurent

AU - Guillaud-Bataille, Marine

AU - Søkilde, Inge

AU - Uhrhammer, Nancy

AU - Demontety, Sophie

AU - Tubeuf, Hélène

AU - Castelain, Gaïa

AU - Jensen, Uffe Birk

AU - Petitalot, Ambre

AU - Krieger, Sophie

AU - Lefol, Cedrick

AU - Moncoutier, Virginie

AU - Boutry-Kryza, Nadia

AU - Roed Nielsen, Henriette

AU - Sinilnikova, Olga

AU - Stoppa-Lyonnet, Dominique

AU - Spurdle, Amanda B.

AU - Teixeira, Manuel R.

AU - Coulet, Florence

AU - Thomassen, Mads

AU - Rouleau, Etienne

PY - 2018/4/3

Y1 - 2018/4/3

N2 - Germline pathogenic variants in the BRCA2 gene are associated with a cumulative high risk of breast/ovarian cancer. Several BRCA2 variants result in complete loss of the exon-3 at the transcript level. The pathogenicity of these variants and the functional impact of loss of exon 3 have yet to be established. As a collaboration of the COVAR clinical trial group (France), and the ENIGMA consortium for investigating breast cancer gene variants, this study evaluated 8 BRCA2 variants resulting in complete deletion of exon 3. Clinical information for 39 families was gathered from Portugal, France, Denmark and Sweden. Multifactorial likelihood analyses were conducted using information from 293 patients, for 7 out of the 8 variants (including 6 intronic). For all variants combined the likelihood ratio in favor of causality was 4.39*1025. These results provide convincing evidence for the pathogenicity of all examined variants that lead to a total exon 3 skipping, and suggest that other variants that result in complete loss of exon 3 at the molecular level could be associated with a high risk of cancer comparable to that associated with classical pathogenic variants in BRCA1 or BRCA2 gene. In addition, our functional study shows, for the first time, that deletion of exon 3 impairs the ability of cells to survive upon Mitomycin-C treatment, supporting lack of function for the altered BRCA2 protein in these cells. Finally, this study demonstrates that any variant leading to expression of only BRCA2 delta-exon 3 will be associated with an increased risk of breast and ovarian cancer.

AB - Germline pathogenic variants in the BRCA2 gene are associated with a cumulative high risk of breast/ovarian cancer. Several BRCA2 variants result in complete loss of the exon-3 at the transcript level. The pathogenicity of these variants and the functional impact of loss of exon 3 have yet to be established. As a collaboration of the COVAR clinical trial group (France), and the ENIGMA consortium for investigating breast cancer gene variants, this study evaluated 8 BRCA2 variants resulting in complete deletion of exon 3. Clinical information for 39 families was gathered from Portugal, France, Denmark and Sweden. Multifactorial likelihood analyses were conducted using information from 293 patients, for 7 out of the 8 variants (including 6 intronic). For all variants combined the likelihood ratio in favor of causality was 4.39*1025. These results provide convincing evidence for the pathogenicity of all examined variants that lead to a total exon 3 skipping, and suggest that other variants that result in complete loss of exon 3 at the molecular level could be associated with a high risk of cancer comparable to that associated with classical pathogenic variants in BRCA1 or BRCA2 gene. In addition, our functional study shows, for the first time, that deletion of exon 3 impairs the ability of cells to survive upon Mitomycin-C treatment, supporting lack of function for the altered BRCA2 protein in these cells. Finally, this study demonstrates that any variant leading to expression of only BRCA2 delta-exon 3 will be associated with an increased risk of breast and ovarian cancer.

U2 - 10.18632/oncotarget.24671

DO - 10.18632/oncotarget.24671

M3 - Article

VL - 9

SP - 17334

EP - 17348

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 25

ER -